FeesSafety
Pluang+

Phase 3 trial confirms ACARIZAX® safe and effective for dust mite allergy in China, approval filing set for 2027

Market News
19 Oct 2026, 16:29 WIB
GlobeNewsWire
View Source
Bullish
Phase 3 trial confirms ACARIZAX® safe and effective for dust mite allergy in China, approval filing set for 2027

ALK Abello's phase 3 trial in China showed that ACARIZAX®, a sublingual immunotherapy tablet for house dust mite allergy, is safe and effective after 24-28 weeks of treatment. The trial met its primary goal with significant symptom improvement and good tolerance among participants aged 12-65. These results align with previous global studies and support ALK's plan to file for regulatory approval in China in the first half of 2027, aiming to address the large under-treated allergy population there.

The phase 3 trial results for ACARIZAX® in China provide context for readers interested in health-sector developments. For readers following health stocks on Pluang as of Oct 19, 2026 20:02 WIB: out of 150 priced US health-sector stocks, 62 rose and 66 fell. Sanofi SA (SNY) traded at USD 39.90 with a 1-day change of -1.75% and a typical hold time of 94 days, contrasting with Summit Therapeutics Inc (SMMT) at USD 14.83 gaining 1.37% and held typically for 17 days, while Bristol-Myers Squibb Co (BMY) was priced at USD 58.95, down 1.34%, with a typical hold time of 92 days.

More News

Super League to release Q3 2026 financial results on Nov 16 after market close

Super League to release Q3 2026 financial results on Nov 16 after market close

Super League Enterprise, a company specializing in audience intelligence and media activation for the gaming industry, announced it will release its financial results for the third quarter ending September 30, 2026, on November 16, 2026, after market...

Company Fundamentals
Neutral
1 hour ago
Stantec reports 9.4% revenue growth and record 20.2% EBITDA margin in Q3 2026, raising 2026 profit outlook

Stantec reports 9.4% revenue growth and record 20.2% EBITDA margin in Q3 2026, raising 2026 profit outlook

Stantec Inc. reported a 9.4% increase in net revenue to $1.9 billion for Q3 2026, driven by organic and acquisition growth. Adjusted EBITDA rose 16.6% to $377.1 million with a record margin of 20.2%, while adjusted EPS grew 23.5% to $1.89. The compan...

Company Fundamentals
Bullish
1 hour ago
Siemens beats earnings estimates and raises medium-term guidance on strong smart infrastructure growth

Siemens beats earnings estimates and raises medium-term guidance on strong smart infrastructure growth

Siemens reported earnings per share of $1.62 and revenue of $26.28 billion, both exceeding analyst expectations. The company saw record orders and double-digit revenue growth in its smart infrastructure and digital industries units, prompting it to r...

Company Fundamentals
Bullish
2 hours ago
ASUS launches AI-ready hardware and software for gamers, creators, and enterprises with local, cloud, and hybrid AI options.

ASUS launches AI-ready hardware and software for gamers, creators, and enterprises with local, cloud, and hybrid AI options.

ASUS has introduced a broad ecosystem of AI-ready hardware and software designed for gamers, creators, developers, and enterprises. The ASUS Agent Computer initiative enables users to deploy AI locally, in the cloud, or via hybrid models, offering co...

Market News
Bullish
3 hours ago
Cosmetic peptide synthesis market to reach $355M by 2032, driven by anti-aging skincare demand and tech advances.

Cosmetic peptide synthesis market to reach $355M by 2032, driven by anti-aging skincare demand and tech advances.

The global cosmetic peptide synthesis market is projected to grow from $274 million in 2027 to $354.85 million by 2032, with a CAGR of 5.34%. Growth is fueled by rising demand for advanced anti-aging skincare ingredients, increased use of peptide-bas...

Market News
Bullish
3 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App